CIP2A作为TP53突变放射抵抗性头颈癌的雷帕霉素治疗靶点
该研究探讨了CIP2A在TP53突变的放射抵抗性头颈癌细胞系中的作用,以及雷帕霉素通过调控CIP2A表达影响HN31细胞对放射反应的效果。结果显示,p53突变刺激CIP2A表达,且CIP2A对抑制辐射诱导的衰老至关重要;单独放疗既未在HN31细胞中诱导细胞毒性,也未完全抑制CIP2A活化;而放疗联合雷帕霉素通过下调CIP2A表达诱导衰老,在体内外均增加放射敏感性。结论提示CIP2A可能作为雷帕霉素通过诱导衰老治疗TP53突变放射抵抗性头颈癌的靶点。
要点
- TP53突变刺激CIP2A表达,CIP2A对抑制辐射诱导的衰老至关重要。
- 单独放疗对HN31细胞无细胞毒性且未完全抑制CIP2A活化。
- 放疗联合雷帕霉素通过下调CIP2A诱导衰老,体内外均增加放射敏感性。
核心结论
- CIP2A可能作为雷帕霉素通过诱导衰老治疗TP53突变放射抵抗性头颈癌的靶点。
研究设计与样本
- 研究使用TP53突变的放射抵抗性头颈癌细胞系,探讨CIP2A的作用及雷帕霉素对HN31细胞放射反应的影响。
主要发现
- CIP2A表达受p53突变刺激,且对抑制辐射诱导的衰老至关重要。
- 单独放疗既未在HN31细胞中诱导细胞毒性,也未完全抑制CIP2A活化。
- 放疗联合雷帕霉素通过下调CIP2A表达诱导衰老,在体内外均增加放射敏感性。
临床怎么用
- 对于TP53突变的放射抵抗性头颈癌,可考虑雷帕霉素联合放疗以诱导衰老并增加放射敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CIP2A may activate multiple oncogenic proteins and promote the proliferation of various cancer cells. METHODS: We investigated that the role of CIP2A in radioresistant head and neck cancer (HNC) cell line with TP53 mutation and the effect of the rapamycin on the response of HN31 with TP53 mutation cells to irradiation related to CIP2A expression. RESULTS: CIP2A expression was stimulated by p53 mutation and critical for the inhibition of senescence induction in response to radiation. The treatment with radiation alone neither induced cytotoxicity in HN31 cells nor completely suppressed the activation of CIP2A. However, the combination of radiation and rapamycin increase the radiosensitivity through the induction of senescence with downregulation of CIP2A expression both in vivo and in vitro. CONCLUSION: Our results suggest that CIP2A may serve as a therapeutic target of rapamycin through induction of senescence in radioresistant HNC with TP53 mutation.
引用
- Kim SH, Lee WH, Seong D, et al. The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation. Head Neck. 2019. PMID: 31268585. doi:10.1002/hed.25868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。